Trials / Completed
CompletedNCT00716534
Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination With ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 145 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-869 | 12.5 mg ABT-869 |
| DRUG | Placebo for ABT-869 | Placebo Comparator (12.5 mg or 7.5 mg) |
| DRUG | ABT-869 | 7.5 mg ABT-869 |
| DRUG | Carboplatin | Carboplatin (AUC 6 mg/mL/min) |
| DRUG | Paclitaxel | Paclitaxel (200 mg/m2) |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2008-07-16
- Last updated
- 2013-04-29
Locations
37 sites across 6 countries: United States, Australia, Brazil, Czechia, Russia, Singapore
Source: ClinicalTrials.gov record NCT00716534. Inclusion in this directory is not an endorsement.